At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 26 enrolled
Drug / intervention
Ramelteondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy
In Brief
A Phase 4 clinical trial evaluating Ramelteon for Insomnia and Major Depressive Disorder. Completed, enrolled 26 participants across 7 sites.
Detailed Summary
The purpose of this study is to investigate exploratorily the effect of ramelteon 8 mg once daily for 8 weeks in the treatment of insomnia patients with depression by using actigraphy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInsomnia, Major Depressive Disorder
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartMay 2017
Primary CompletionJan 2018
TodayJul 2026
First PostedJan 29, 2016
Enrollment StartMay 9, 2017
Primary CompletionJan 31, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.4 years ago
Interventions
Ramelteondrug
Ramelteon tablets